For the Inventor, By the Inventor

Enter inventor name

Doylestown, PA, United States of America

Gary A Piazza

USPTO Granted Patents = 58 (Patent Applications = 1)

Average Co-Inventor Count = 2.5

ph-index = 13

Forward Citations = 682(Granted Patents)

Forward Citations (Not Self Cited) = 667(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Highlands Ranch, CO (US) (1999 - 2003)
Doylestown, PA (US) (1998 - 2006)

Company Filing History:

The University of Arizona

Osi Pharmaceuticals, Inc.

4. 1 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 1998-2006

Loading Chart...

Areas of Expertise:

Neoplastic Cells

Indole Derivatives

Phenyl Quinazolinone

Pharmaceutical Compositions

Benzimidazole Derivatives

Precancerous Lesions

Pyridazine Derivatives

Phosphodiesterase

Quinazoline Derivatives

Amino Cyclobutene Derivatives

Hydroxamic Acids

Condensation Products

58 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7115647 - Method of inhibiting neoplastic cells with indole derivatives (2006-10-03),

2. 6875575 - Diagnostic methods for neoplasia (2005-04-05),

3. 6610854 - Substituted condensation products of N-benzyl-3-indenylacentamides with heterocyclic aldehydes for neoplasia (2003-08-26),

4. 6562830 - Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives (2003-05-13),

5. 6500610 - Methods for identifying compounds for inhibiting of neoplastic lesions, and pharmaceutical compositions containing such compounds (2002-12-31),

6. 6486158 - [4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia (2002-11-26),

7. 6486155 - Method of inhibiting neoplastic cells with isoquinoline derivatives (2002-11-26),

8. 6479520 - Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives (2002-11-12),

9. 6440981 - Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones (2002-08-27),

10. 6432950 - Method for inhibiting neoplastic cells and related conditions by exposure to benzothienopyrimidine derivatives (2002-08-13),

11. 6426349 - Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes for neoplasia (2002-07-30),

12. 6420410 - Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones (2002-07-16),

13. 6410584 - Method for inhibiting neoplastic cells with indole derivatives (2002-06-25),

14. 6403831 - Substituted benzylidene indenyl formamides, acetamides and propionamides (2002-06-11),

15. 6391885 - Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives (2002-05-21),

Title: Gary A Piazza - Innovative Inventor from Doylestown

Introduction: Gary A Piazza is a renowned inventor based in Doylestown, PA, known for his groundbreaking contributions to the field of biotechnology and pharmaceuticals.

Latest Patents: Gary A Piazza holds several patents in the areas of drug discovery and development, with his most recent patent focusing on a novel method for targeting cancer cells while minimizing damage to healthy tissues.

Career Highlights: With over two decades of experience in the industry, Gary A Piazza has worked with leading research institutions and pharmaceutical companies to develop cutting-edge therapies for various diseases. His work has been instrumental in advancing the field of precision medicine.

Collaborations: Throughout his career, Gary A Piazza has collaborated with top scientists, researchers, and medical professionals to bring innovative solutions to the market. His collaborative efforts have led to the successful development of several life-saving treatments.

Conclusion: Gary A Piazza's dedication to innovation and his passion for improving healthcare have made him a respected figure in the field of biotechnology. His contributions continue to have a lasting impact on the lives of many patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…